Activity of a new liposomal formulation of amphotericin B against two strains of leishmania infantum in a murine model

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1731-1734

  Paul, Muriel ^a,d   Durand, Rémy ^b   Fessi, Hatem ^c   Rivollet, Daniele ^b   Houin, René ^b   Astier, Alain ^a   Deniau, Michèle ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c UNIVERSITÉ LYON 1   (France)

^d NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG FORMULATION; DRUG LIVER LEVEL; LEISHMANIA DONOVANI; LEISHMANIASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN;

EID: 0030795383     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1731     Document Type: Article

References (35)

1. Altes, J., A. Salas, M. Riera, M. Udina, A. Galmès, J. Balanzat, A. Ballesteros, J. Buades, F. Salva, and C. Villalonga. 1991. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS. 5:201-207.
2. Alvar, J. 1992. Prevalence of Leishmania infection among AIDS patients. Lancet 339:1427.
3. Berman, I. D., W. L. Hanson, W. L. Chapman, C. R. Alving, and G. Lopez-Berenstein. 1986. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob. Agents Chemother. 30:847-851.
4. Bryceson, A. D. M. 1987. Therapy in man, p. 847-907. In W. Peters and R. Killick-Kendrick (ed.), The leishmaniases in biology and medicine, vol. 2. Clinical aspects and control. Academic Press, London, United Kingdom.
5. Carter, K. C., T. F. Dolan, J. Alexander, A. J. Baillie, and C. McColgan. 1989. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J. Pharm. Pharmacol. 41:87-41.
6. 5a. Council for International Organizations of Medical Sciences. 1985. Guiding principles for biomedical research. Council for International Organizations of Medical Sciences, Geneva, Switzerland.
7. Croft, S. L., R. N. Davidson, and E. A. Thornton. 1991. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J. Antimicrob. Chemother. 28(Suppl. B):111-118.
8. Davidson, R. N., S. L. Croft, A. Scott, M. Maini, A. H. Moody, and A. D. M. Bryceson. 1991. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 337:1061-1062.
9. Davidson, R. N., L. Di Martino, L. Gradoni, R. Giacchino, R. Russo, G. B. Gaeta, R. Pempinello, S. Scott, F. Raimondi, A. Cascio, T. Prestileo, L. Caldeira, R. J. Wilkinson, and A. D. M. Bryceson. 1994. Liposomal amphotericin B (Ambisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q. J. Med. 87:75-81.
10. Davidson, R. N., L. Di Martino, L. Gradoni, R. Giacchino, G. B. Gaeta, R. Pempinello, S. Scotti, A. Cascio, E. Castagnola, A. Maisto, M. Gramiccia, D. Di Caprio, R. J. Wilkinson, and A. D. M. Bryceson. 1996. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (Ambisome). Clin. Infect. Dis. 22:938-943.
11. Dereure, J., J. Reynes, F. Pratlong, I. Lamaury, J. A. Rioux, F. Janbon, and J. P. Dedet. 1995. Visceral leishmaniasis in HIV-infected patients in the south of France. Bull. W. H. O. 73:245-246.
12. Desjeux, P. 1996. Leishmaniasis: public health aspects and control. Clin. Dermatol. 14:417-423.
13. Durand, R., M. Paul, D. Rivollet, R. Houin, A. Astier, and M. Deniau. Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. Int. J. Parasitol., in press.
14. Fessi, H., S. Stainmesse, J. P. Devissaguet, and F. Puisieux. June 1988. French patent 8,8118,874.
15. Fillola, G., J. X. Corberand, P. F. Laharrague, H. Levenes, P. Massip, and P. Recco. 1992. Peripheral intramonocytic leishmanias in an AIDS patient. J. Clin. Microbiol. 30:3284-3285.
16. Fusaï, T., M. Deniau, R. Durand, C. Bories, M. Paul, D. Rivollet, A. Astier, and R. Houin. 1994. Action of pentamidine bound nanoparticles against Leishmania on an in vivo model. Parasite 1:319-324.
17. Gangneux, J. P., A. Sulahian, Y. J. F. Garin, R. Farinotti, and F. Derouin. 1996. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of Ambisome. Antimicrob. Agents Chemother. 40:1214-1218.
18. Gondal, J. A., R. P. Swartz, and A. Rahman. 1989. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob. Agents Chemother. 33:1544-1548.
19. Gradoni, L., R. N. Davidson, S. Orsini, P. Betto, and M. Giambenedetti. 1993. Activity of liposomal amphotericin B (Ambisome) against Leishmania infantum and tissue distribution in mice. J. Drug Target. 1:311-316.
20. Gradoni, L., A. Bryceson, and P. Desjeux. 1995. Treatment of Mediterranean visceral leishmaniasis. Bull. W. H. O. 73:191-197.
21. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2):S133-S144.
22. Legrand, P., A. Vertut-Doï, and J. Bolard. 1996. Comparative internalization and recycling of different amphotericin B formulations by a macrophage-like cell line. J. Antimicrob. Chemother. 37:519-533.
23. Matheron, S., A. Cabie, F. Parquin, C. Mayaud, P. Roux, M. Antoine, C. Chougnet, and J. P. Coulaud. 1992. Visceral leishmaniasis in HIV infection: unusual presentation with pleuropulmonary involvement, and effect of secondary prophylaxis. AIDS 6:238-240. (Letter.)
24. Mishra, M., U. K. Biswas, A. M. Jha, and A. B. Khan. 1994. Amphotericin versus sodium stibogluconate in first-line treatment of Indian Kala-azar. Lancet 344:1599-1600.
25. Montalban, C., J. L. Calleja, A. Erice, F. Laguna, B. Clotet, D. Podzamczer, J. Cobbo, J. Mallolas, M. Yebra, A. Gallego, and the Co-operative Group for the Study of Leishmaniasis in AIDS. 1990. Visceral leishmaniasis in patients infected with human immunodeficiency virus. J. Infect. 21:261-270.
26. New, R. R. C., M. L. Chance, and S. Heath. 1981. Antileishmanial activity of amphotericin and other antifungal agents in liposomes. J. Antimicrob. Chemother. 8:371-381.
27. Oliva, G., L. Gradoni, P. Ciaramella, R. De Luna, L. Cortese, S. Orsini, R. N. Davidson, and A. Persechino. 1995. Activity of liposomal amphotericin B (Ambisome) in dogs naturally infected with Leishmania infantum. J. Antimicrob. Chemother. 36:1013-1019.
28. Olsen, S. J., M. R. Swerdel, B. Blue, J. M. Clark, and D. P. Bonner. 1991. Tissue distribution of amphotericin B lipid complex in laboratory animals. J. Pharm. Pharmacol. 43:831-835.
29. Peters, B. S., D. Fish, R. Golden, D. A. Evans, A. D. M. Bryceson, and A. J. Pinching. 1990. Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q. J. Med. 77:1101-1111.
30. Proffitt, R. T., A. Satorius, S. M. Chiang, L. Sullivan, and J. P. Adler-Moore. 1991. Pharmacology and toxicology of liposomal formulation of amphotericin B (Ambisome) in rodents. J. Antimicrob. Chemother. 28(Suppl. B):49-61.
31. Rosenthal, E., P. Marty, I. Poizot-Martin, J. Reynes, F. Pratlong, A. Lafeuillade, D. Jaubert, O. Boulat, J. Dereure, F. Gambarelli, J. A. Gastaut, P. Dujardin, P. Dellamonica, and J. P. Cassuto. 1995. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans. R. Soc. Trop. Med. Hyg. 89:159-162.
32. Scaglia, M., M. Villa, S. Gatti, and F. Fabio. 1989. Cutaneous leishmaniasis in acquired immunodeficiency syndrome. Trans. R. Soc. Trop. Med. Hyg. 83:338-339.
33. Stauber, L. A., E. M. Franchino, and J. Grun. 1958. An eight-day method for screening compounds against Leishmania donovani in golden hamsters. J. Protozool. 5:269-273.
34. Torre-Cisneros, J., J. L. Villanueva, J. M. Kindelan, R. Jurado, and P. Sanchez-Guijo. 1993. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 17:625-627.
35. Wang, L. H., P. C. Smith, and K. L. Anderson. 1992. High-performance liquid chromatographic analysis of amphotericin B in plasma, blood, urine and tissues for pharmacokinetic and tissue distribution studies. J. Chromatogr. 579:259-268.